{"log_id": 1459195915798450207, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 0.012599, "average": 0.955233, "min": 0.444322}, "location": {"width": 781, "top": 162, "height": 43, "left": 214}, "words": "药物是否经人乳汁分泌不确定哺乳小鼠给予单剂卡培他滨口服后可见乳汁事含大量"}, {"probability": {"variance": 0.021261, "average": 0.932585, "min": 0.484274}, "location": {"width": 822, "top": 203, "height": 40, "left": 177}, "words": "卡培他滨代谢产物。由手卡增他滨可能致喵乳幼儿出斑严重不良反应,建议罐乳期女在接"}, {"probability": {"variance": 0.018646, "average": 0.950555, "min": 0.498921}, "location": {"width": 251, "top": 252, "height": 31, "left": 177}, "words": "受卡培他滨治疗时停比授乳"}, {"probability": {"variance": 2e-06, "average": 0.998248, "min": 0.995396}, "location": {"width": 115, "top": 295, "height": 25, "left": 184}, "words": "【儿童用药】"}, {"probability": {"variance": 0.010584, "average": 0.973331, "min": 0.493223}, "location": {"width": 471, "top": 326, "height": 34, "left": 220}, "words": "卡培他滨对18岁以下患者的安全性和疗效尚来证实"}, {"probability": {"variance": 3.6e-05, "average": 0.993799, "min": 0.98239}, "location": {"width": 117, "top": 372, "height": 26, "left": 184}, "words": "【老年用药】"}, {"probability": {"variance": 0.011452, "average": 0.96499, "min": 0.364973}, "location": {"width": 777, "top": 397, "height": 42, "left": 223}, "words": "卡培他滨单药治疗转移性结直肠,60-79岁患者中胃肠道毒性的发生率与总体人群近"}, {"probability": {"variance": 0.001517, "average": 0.988405, "min": 0.760264}, "location": {"width": 821, "top": 436, "height": 41, "left": 179}, "words": "似。可逆的3或4级胃肠道不良反应在80岁以上的患者中发生率较高,如腹泻、恶心、"}, {"probability": {"variance": 0.006196, "average": 0.967698, "min": 0.648022}, "location": {"width": 821, "top": 476, "height": 40, "left": 180}, "words": "吐(见特殊用药指南)。当卡培他滨与其他药物联用时,老年患者(65岁)与年轻患者粗比出"}, {"probability": {"variance": 0.00014, "average": 0.993104, "min": 0.943461}, "location": {"width": 820, "top": 514, "height": 41, "left": 181}, "words": "现更多的3级、4级及导致停药的不良反应。卡培他滨联合多西紫杉醇用于60岁以上患者"}, {"probability": {"variance": 0.001796, "average": 0.987646, "min": 0.731569}, "location": {"width": 819, "top": 552, "height": 44, "left": 183}, "words": "的安全性分析显示,治疗相关3和4级不良事件、治疗相关的严重不良事件以及因不良事件"}, {"probability": {"variance": 0.001008, "average": 0.985101, "min": 0.85452}, "location": {"width": 411, "top": 599, "height": 34, "left": 182}, "words": "提前退出治疗的发生率高于60岁以下患者组"}, {"probability": {"variance": 9.6e-05, "average": 0.994395, "min": 0.968744}, "location": {"width": 160, "top": 642, "height": 28, "left": 189}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.012688, "average": 0.955049, "min": 0.440986}, "location": {"width": 777, "top": 670, "height": 40, "left": 229}, "words": "香豆紫类抗凝:在使用卡培滨并伴随华法林及苯丙香素等香豆素衍生物类抗凝剂"}, {"probability": {"variance": 0.008868, "average": 0.978002, "min": 0.411342}, "location": {"width": 822, "top": 707, "height": 43, "left": 185}, "words": "治疗的患者中,已有凝血指标改变和或出血的报道。这些情况发生于卡培他滨治疗后数"}, {"probability": {"variance": 0.001651, "average": 0.987452, "min": 0.748186}, "location": {"width": 820, "top": 747, "height": 41, "left": 186}, "words": "至数月内,一些患者出现在卡培他滨停用1个月内。在一项药物相互作用的研究中,单次服"}, {"probability": {"variance": 0.017438, "average": 0.950814, "min": 0.397326}, "location": {"width": 820, "top": 784, "height": 44, "left": 187}, "words": "用20mg华法林后给予卡培他滨治疗,S华法林的平均AUC增加579,INR增加91%。对"}, {"probability": {"variance": 0.000604, "average": 0.990445, "min": 0.866764}, "location": {"width": 795, "top": 825, "height": 40, "left": 190}, "words": "使用卡培他滨同时口服香豆素类衍生物抗凝剂的患者,应常规监测其抗凝参数(INR或PT"}, {"probability": {"variance": 0.015785, "average": 0.955166, "min": 0.558448}, "location": {"width": 234, "top": 877, "height": 26, "left": 189}, "words": "并相应调整抗凝剂的剂量"}, {"probability": {"variance": 0.001824, "average": 0.983425, "min": 0.736464}, "location": {"width": 776, "top": 904, "height": 41, "left": 233}, "words": "细胞色素P-4502C9底物:卡培他滨与其他已知经细胞色素P-4502C9代谢药物间的相"}, {"probability": {"variance": 0.000103, "average": 0.99604, "min": 0.948275}, "location": {"width": 522, "top": 948, "height": 37, "left": 192}, "words": "互作用尚未进行正式研究。卡培他滨应慎与此类药物同用"}, {"probability": {"variance": 0.001872, "average": 0.97911, "min": 0.831594}, "location": {"width": 778, "top": 983, "height": 41, "left": 234}, "words": "苯妥英:据报道,卡培他滨和苯妥英同时服用会增加苯妥英的血浆浓度。尚未进行卡培"}, {"probability": {"variance": 6e-06, "average": 0.998042, "min": 0.989894}, "location": {"width": 822, "top": 1023, "height": 39, "left": 191}, "words": "他滨与苯妥英药物相互作用的正式研究,但推测相互作用的机制可能为卡培他滨抑制"}, {"probability": {"variance": 0.003166, "average": 0.97529, "min": 0.687839}, "location": {"width": 815, "top": 1062, "height": 40, "left": 198}, "words": "CYP2C9同工酶(见香豆素类抗凝剂。对使用卡培他滨同时服用苯妥英的患者,应常规监测"}, {"probability": {"variance": 1e-06, "average": 0.998922, "min": 0.997405}, "location": {"width": 167, "top": 1112, "height": 25, "left": 194}, "words": "苯妥英的血浆浓度"}, {"probability": {"variance": 0.003301, "average": 0.97878, "min": 0.710317}, "location": {"width": 766, "top": 1140, "height": 38, "left": 237}, "words": "药物食物相互作用:在所有的临床试验中都指导患者在餐后30分钟内服用卡墙他滨"}, {"probability": {"variance": 0.002358, "average": 0.989789, "min": 0.69539}, "location": {"width": 789, "top": 1180, "height": 38, "left": 196}, "words": "现有的安全性和疗效资料都是基于与食物一同服用,因此建议卡培他滨与食物一同服用"}, {"probability": {"variance": 0.009181, "average": 0.962995, "min": 0.605202}, "location": {"width": 776, "top": 1218, "height": 38, "left": 238}, "words": "制酸剂:在恶性肿瘤患者中研究了一种含氢氧化铝和氢氧化镁的制酸剂 Maalox)对卡培"}, {"probability": {"variance": 0.007796, "average": 0.960611, "min": 0.595328}, "location": {"width": 817, "top": 1259, "height": 36, "left": 197}, "words": "他滨药代动力学的影响。卡培他滨及其一种代谢产物(5-DFCR)的血浆浓度轻微增加;对三"}, {"probability": {"variance": 0.001877, "average": 0.975871, "min": 0.825933}, "location": {"width": 455, "top": 1304, "height": 27, "left": 197}, "words": "种主要代谢物(5-DFUR、5-FU和FBAL)没有影响"}, {"probability": {"variance": 0.006211, "average": 0.974279, "min": 0.571882}, "location": {"width": 774, "top": 1337, "height": 37, "left": 241}, "words": "甲酰四氢叶酸(亚叶酸):在恶性肿瘤患者中研究了甲酰四氢叶酸对卡培他滨药代动力学"}, {"probability": {"variance": 0.012927, "average": 0.966289, "min": 0.410425}, "location": {"width": 816, "top": 1379, "height": 33, "left": 198}, "words": "的影响,结果显示其对卡培他滨及其代谢产物的药代动力学无影响,但甲酰四氢叶酸对卡"}, {"probability": {"variance": 2.1e-05, "average": 0.998103, "min": 0.977734}, "location": {"width": 459, "top": 1422, "height": 31, "left": 198}, "words": "他滨的药效学有影响,且可能增加卡培他滨的毒性"}, {"probability": {"variance": 0.000339, "average": 0.992837, "min": 0.908333}, "location": {"width": 774, "top": 1458, "height": 34, "left": 242}, "words": "索立夫定及其类似物:文献显示,由于索立夫定对二氢嘧啶脱氢酶的抑制作用,索立夫"}, {"probability": {"variance": 0.00059, "average": 0.991722, "min": 0.874877}, "location": {"width": 817, "top": 1500, "height": 30, "left": 199}, "words": "定与5-氟尿嘧啶药物间存在显著的临床相互作用。这种相互作用导致氟嘧啶毒性升高,有"}], "language": 3}